Drugs for increasing oxygen transrort and their potential use in doping a review

Sports Medicine

Volumn 33, Issue 3, 2003, Pages 187-212

  Gaudard, Aurelie ^a   Varlet Marie, Emmanuelle ^a   Bressolle, Francoise ^a   Audran, Michel ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ADENOVIRUS VECTOR; BIS 3,5 DIBROMOSALICYLFUMARATE; BLOOD SUBSTITUTE; DOXYCYCLINE; EFAPROXIRAL; EPOMAX; ERYTHROPOIETIN; ERYTHROPOIETIN MIMETIC PEPTIDE; ERYTHROPOIETIN RECEPTOR; ERYTHROPOIETIN RECEPTOR BINDER; ERYTHROPOIETIN RECEPTOR DERIVED PEPTIDE; FLUOSOL; GENE ACTIVATED ERYTHROPOIETIN; HEMASSISST; HEMOGLOBIN; HEMOSPAN; MACROGOL; MIFEPRISTONE; N 3 [2 (4 BIPHENYL) 6 CHLORO 5 METHYL]INDOYLACETYLLYSINE METHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYCYTE; OXYFLUOR; PERFLUORO COMPOUND; PERFLUORODECALIN; PERFLUORODICHLOROOCTANE; PERFLUOROOCTYL BROMIDE; PERFTORAN; PHOSPHATASE; POLYMERIZED HEMOGLOBIN; RAFFINOSE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN ALPHA; RECOMBINANT ERYTHROPOIETIN BETA; RECOMBINANT ERYTHROPOIETIN OMEGA; RECOMBINANT HEMOGLOBIN; REPOXYGEN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENO ASSOCIATED VIRUS; ALLOSTERISM; ALTITUDE; ANAPHYLAXIS; AREA UNDER THE CURVE; ATHLETE; BLOOD OXYGENATION; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; BLOOD VISCOSITY; BRAIN TUMOR; CHILL; CLINICAL TRIAL; DOPING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; ENDURANCE; ENZYME INHIBITION; ERYTHROCYTE APLASIA; ERYTHROPOIESIS; FEVER; GENE ACTIVATION; GENE THERAPY; HEADACHE; HEMATOPOIETIC CELL; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; LABORATORY; LOW BACK PAIN; MUSCLE CONTRACTION; MYALGIA; NAUSEA; OXIDATION; PERFORMANCE; REVIEW; RISK; SAFETY; SICKLE CELL CRISIS; SIDE EFFECT; SPORT; TACHYCARDIA; THROMBOSIS; VASOCONSTRICTION; VIRAL GENE DELIVERY SYSTEM;

ALTITUDE; BLOOD SUBSTITUTES; DOPING IN SPORTS; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; EXERCISE; GENE THERAPY; HEMOGLOBINS; HUMANS; MOLECULAR MIMICRY; OXYGEN; OXYGEN CONSUMPTION; PHYSICAL ENDURANCE; SUBSTANCE ABUSE DETECTION;

EID: 0037258964     PISSN: 01121642     EISSN: None     Source Type: Journal    
DOI: 10.2165/00007256-200333030-00003     Document Type: Review

References (202)

1. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. Scand J Med Sci Sports 1991; 1: 88-93
2. Vandegriff KD. Haemoglobin-based oxygen carriers. Expert Opin Investig Drugs 2000 Sep; 9 (9): 1967-84
3. McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free haemoglobins: implications for the design of haemoglobin-based oxygen carriers. Biophys Chem 2001 Aug 30; 92 (1-2): 103-7
4. Stryer L. Biochemistry. 4th ed. New York: WH Freeman and Company, 1995: 159-60
5. Benesch R, Benesch RE. Intracellular organic phosphates as regulators of oxygen release by haemoglobin. Nature 1969 Feb 15; 221 (181): 618-22
6. Benesch R, Benesch RE, Yu CI. Reciprocal binding of oxygen and diphosphoglycerate by human haemoglobin. Proc Natl Acad Sci 1968 Feb; 59: 526-32
7. Ekblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion of red blood cells. J Appl Physiol 1982; 33: 175-80
8. Ekblom B, Wilson G, Astrand PO. Central circulation during exercise after venesection and reinfusion of red blood cells. J Appl Physiol 1976; 40: 379-83
9. Buick FJ, Glehill N, Froese AB, et al. Effect of induced erythrocythaemia on aerobic power capacity. J Appl Physiol 1980; 48: 636-42
10. Kanstrup IL, Ekblom B. Acute hypervolemia, cardiac performance and aerobic power during exercise. J Appl Physiol 1982; 52: 1186-91
11. Gledhill N. The influence of altered blood volume and oxygen-transport capacity on aerobic performance. Exerc Sport Sci Rev 1985; 13: 75-93
12. Berglund B, Hemmingsson P, Birgegard G. Detection of autologous blood transfusions in cross-country skiers. Int J Sports Med 1987; 8: 66-70
13. Ekblom BT. Blood boosting and sport. Baillières Best Pract Res Clin Endocrinol Metab 2000; 14 (1): 89-98
14. Gledhill N. Blood doping and related issues: a brief review. Med Sci Sports Exerc 1982; 14: 183-9
15. Gledhill N, Warburton D, Jamnick V. Haemoglobin, blood volume, cardiac function, and aerobic power. Can J Appl Physiol 1999; 24: 54-65
16. Gladwell F, Jopke T. Ethics of blood doping. Phys Sports Med 1985; 13: 145-51
17. Brien AJ, Simon TL. The effects of red blood cell infusion on 10-km race time. JAMA 1987 May; 257: 2761-5
18. Klein HG. Blood transfusion and athletics games people play. N Engl J Med 1985 Mar; 312 (13): 854-6
19. Berglund B. Development of techniques for the detection of blood doping in sports. Sports Med 1988 Feb; 5 (2): 127-35
20. d'Onofrio G, Zini G. Addendeum to strategies to deter blood doping in sports [letter]. Haematologica 2002; 87 (7): ELT31
21. Jelkmann W, Metzen E. Erythropoietin in the control of red cell production. Ann Anat 1996; 178: 391-403
22. Ratcliffe PJ, Ebert BL, Ferguson DJ, et al. Regulation of the erythropoietin gene. Nephrol Dial Transplant 1995; 10 Suppl. 2: 18-27
23. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1998; 242: 1412-5
24. Beck I, Weinmann R. Caro J. Characterization of the hypoxia-responsive enhancer in the human erythropoietin shows presence of hypoxia-inducible 120 Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 1993; 82: 704-11
25. Nissenson AR. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001 Dec; 38 (6): 1390-7
26. Moriya H, Maitani Y, Shimoda N, et al. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm Res 1997; 14 (11): 1621-8
27. Johnson DL, Jolliffe LK. Erythropoietin mimetic peptides and the future. Nephrol Dial Transplant 2000 Dec; 15 (9): 1274-7
28. Kuai L, Wu C, Qiu Q, et al. Plasminogen activator inhibitor-1 fused with erythropoietin (EPO) mimetic peptide (EMP) enhances the EPO activity of EMP. J Pept Res 2000 Aug; 56 (2): 59-62
29. Middleton SA, Barbone FP, Johnson DL, et al. Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. J Biol Chem 1999 May; 274 (20): 14163-9
30. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283 (5404): 990-3
31. Samaja M. Hypoxia-dependent protein expression: erythropoietin. High Alt Med Biol 2001; 2: 155-63
32. Caro J. Hypoxia regulation of gene transcription. High Alt Med Biol 2001; 2: 145-54
33. Hurtado A. Animals in high altitudes: resident man. Handbook of physiology: adaptation to environment. Washington, DC: American Physiology Society, 1964: 843-60
34. Bailey MD, Davies B. Physiological implications of altitude training for endurance performance at sea level: a review. Br J Sports Med 1997 Sep; 31 (3): 183-90
35. Beall CM, Blangero J, Williams-Blangero S, et al. Major gene for percent of oxygen saturation of arterial haemoglobin in Tibetan highlanders. Am J Phys Anthropol 1994 Nov; 95 (3): 271-6
36. Boning D, Rojas J, Serrato M, et al. Haemoglobin mass and peak oxygen uptake in untrained and trained residents of moderate altitude. Int J Sports Med 2001; 22: 572-8
37. Ward MP, Milledge JS, West JB. High altitude medicine and physiology. 2nd ed. London: Chapman and Hall Medical, 1995
38. Winslow RM, Monge CC. Hypoxia, polycythemia and chronic mountain sickness. Baltimore (MD): John Hopkins University Press, 1987
39. Milledge JS. High altitude. In: Harries M. Williams C, Stabish W, et al., editors. Oxford textbook of sports medicine. London: Oxford University Press, 1994: 217-30
40. Levine BD, Stray-Gundersen J. A practical approach to altitude training: where to live and train for optimal performance enhancement. Int J Sports Med 1992; 13 Suppl. 1: S209-12
41. Stray-Gundersen J, Levine BD. 'Living high and training low' can improve sea level performance in endurance athletes. Br J Sports Med 1999 Jun; 33 (3): 150-4
42. Levine BD, Stray-Gundersen J, Duhaime G, et al. Living high, training low: the effect of altitude acclimatization/normoxic training in trained runners [abstract]. Med Sci Sports Exerc 1991; 23 Suppl. 4: 25S
43. Stray-Gundersen J, Chapman RF, Levine BD. 'Living high-training low' altitude training improves sea level performance in male and female elite runners. J Appl Physiol 2001; 91: 1113-20
44. Geiser J, Vogt M, Billeter R, et al. Training high, living low: changes of aerobic performance and muscle structure with training at simulated altitude. Int J Sports Med 2001 Nov; 22: 579-85
45. Hoppeler H, Vogt M. Hypoxia training for sea-level performance: training high-living low. Adv Exp Med Biol 2001; 502: 61-73
46. Levine BD, Stray-Gundersen J. The effects of altitude training are mediated primarily by acclimatization, rather than by hypoxic exercise. Adv Exp Med Biol 2001; 502: 75-88
47. Dick FW. Training at altitude in practice. Int J Sports Med 1992 Oct; 13: 203-5
48. Berglund B. High-altitude training: aspects of haematological adaptation. Sports Med 1992 Nov; 14 (5): 289-303
49. Rusko HK, Leppavuori A, Makela P, et al. Living high, training low: a new approach to 48 altitude training at sea level in athletes [abstract]. Med Sci Sports Exerc 1995; 27 Suppl. 5: 6S
50. Wilber RL. Current trends in altitude training. Sports Med 2001; 31: 249-65
51. Laitinen H, Alopaeus K, Heikkinen R, et al. Acclimatization to living in normobaric hypoxia and training at sea level in runners [abstract]. Med Sci Sports Exerc 1995; 27 Suppl. 5: 109S
52. Mattila V, Rusko H. Effect of living high and training low on sea level performance in cyclists [abstract]. Med Sci Sports Exerc 1996; 28 Suppl. 5: 157S
53. Piehl-Aulin K, Svedenhag J, Wide L, et al. Short-term intermittent normobaric hypoxia-haematological physiological and mental effect. Scand J Med Sci Sports 1998; 8: 132-7
54. Ashenden MJ, Gore CJ, Dobson GP, et al. Simulated moderate altitude elevates serum erythropoietin but does not increase reticulocyte production in well-trained runners. Eur J Appl Physiol 2000; 81: 428-35
55. Rodriguez FA, Ventura JL, Casas M, et al. Erythropoietin acute reaction and haematological adaptations to short, intermittent hypobaric hypoxia. Eur J Appl Physiol 2000; 82: 170-7
56. Nummela A. Acclimatization to altitude and normoxic training improve 400m running performance at sea level. J Sports Sci 2000; 18: 411-9
57. Ashenden MJ, Gore CJ, Martin DT, et al. Effects of a 12-day 'live high train low' camp on reticulocytes production and haemoglobin mass in elite female road cyclists. Eur J Appl Physiol 1999; 80: 472-8
58. Ashenden MJ, Gore CJ, Dobson GP, et al. 'Live high, train low' does not change the total haemoglobin mass of male endurance athletes sleeping at a simulated altitude of 3000m for 23 nights. Eur J Appl Physiol 1999; 80: 479-84
59. Morris DM, Kearney JT, Burke ER. The effects of breathing supplemental oxygen during altitude training on cycling performance. J Sci Med Sport 2000; 3: 165-75
60. Chick TW, Stark DM, Murata GH. Hyperoxic training increases work capacity after maximal training at moderate altitude. Chest 1993; 104: 1759-62
61. Knaupp W, Khilmani S, Sherwood J, et al. Erythropoietin response to acute normobaric hypoxia in humans. J Appl Physiol 1992; 73: 837-40
62. Frey WO, Zenhausem R, Colombani PC, et al. Influence of intermittent exposure to normobaric hypoxia on hematological indexes and exercise performance [abstract]. Med Sci Sports Exerc 2000; 32 Suppl. 5: 65S
63. Terrados N, Melichna J, Sylven C, et al. Effects of training at simulated altitude on performance and muscle metabolic capacity in compefitive road cyclists. Eur J Appl Physiol 1988; 57: 203-9
64. Meeuwsen T, Hendrksen IJM, Holewijn M, et al. Training-induced increases in sea-level performance is enhanced by acute intermittent hypobaric hypoxia: a 2 year crossover study [abstract]. Med Sci Sports Exerc 2000; 32 Suppl. 5: 251S
65. Berglund B, Gennser M, Omhagen H, et al. Erythropoietin concentrations during 10 days of normobaric hypoxia under controlled environmental circumstances. Acta Physiol Scand 2002 Mar; 174 (3): 225-9
66. Jacobson LO, Goldwasser E, Fried W, et al. Role of the kidney in erythropoiesis. Nature 1957; 179: 633-4
67. Fried W. The liver as a source of extrarenal erythropoietin production. Blood 1972; 40: 671-7
68. Fisher JW. Extrarenal erythropoietin production. J Lab Clin Med 1979; 93: 695-9
69. Braumann KM, Nonnast-Daniel B, Boning D, et al. Improved physical performance after treatment of renal anaemia with recombinant human erythropoietin. Nephron 1991; 58: 129-34
70. Horina JH, Schwaverger G, Brussee H, et al. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 1993; 8: 1219-22
71. Grunze M, Kohlmann M, Mulligan M, et al. Mechanisms of improved physical performance of chronic haemodialysis patients after erythropoietin treatment. Am J Nephrol 1990; 10 Suppl. 2: 15-8
72. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988 Jan 16; I (8577): 97-100
73. Piron M, Loo M, Gothot A, et al. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood 2001 Jan 15; 97 (2): 442-8
74. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002 Feb 14; 346 (7): 469-75
75. Wide L, Bengtsson C, Berglund B, et al. Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 1995; 27: 1569-76
76. Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med 2002; 32 (2): 125-42
77. Parisotto R, Gore CJ, Emslie KR, et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000; 85: 564-72
78. Parisotto R, Wu M, Ashenden MJ, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001 Feb; 86 (2): 128-37
79. Lasne F. Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 2001 Jul 1; 253 (1-2): 125-31
80. Bren A, Kandus A, Varl J, et al. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 2002 Feb; 26 (2): 91-7
81. Sikole A, Spasovski G, Zafirov D, et al. Epoetin omega for treatment of anaemia in maintenance hemodialysis patients. Clin Nephrol 2002 Mar; 57 (3): 237-45
82. Egrie JC, Grant JR, Gillies DK, et al. The role of carbohydrate on the biological activity of erythropoietin [abstract]. Glycoconj J 1993; 10: 263
83. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985; 116: 2293-9
84. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 (3 Suppl.): 3-13
85. Ibbotson T, Goa KL. Darbepoietin alfa. Drugs 2001; 61 (14): 2097-104
86. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5
87. Korbett SM. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int 1993; 43: 111-9
88. Vanrenterghem Y, Barany P, Mann J, et al. Novel erythropoiesis stimulating protein (NESP) maintains haemoglobin (Hgb) in ESRD patients with administered once weekly or once every other week [abstract]. J Am Soc Nephrol 1999; 10: 1365A
89. Coyne D, Ling ND, Toto R, et al. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-HuEpo) [abstract]. J Am Soc Nephrol 2000; 11: 1380A
90. Graf H, Lacombe JL, Braun J, et al. Novel erythropoiesis stimulating protein (NESP) effectively maintains haemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-HuEpo) in dialysis patients [abstract]. J Am Soc Nephrol 2000; 11: 1317A
91. Amgen Inc. Aranesp® physician package insert. California: 2001
92. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 Suppl. 3: 14-21
93. Clarey C. In the arena: no bronze, silver or gold: an obvious answer to drug users [online]. Herald Tribune 2002 Mar 22. Available from URL: http://www.iht.com/ihtsearch.php?id= 52056&owner=(International%20Herald%20Tribune)&date= 00000000000000 [Accessed 2003 Jan 8]
94. De Bree F. Genomics-based drugs in R&D the promise of a new era [online]. Genomics Based Drugs Data Rep Regen Ther 2001; 1 (1): 5-19. Available from URL: www.prous.com/journals/gddr/sample/html/gddr010005/gddr010005.html [Accessed 2002 Sep 10]
95. Kedar E, Rutkowski Y, Braun E, et al. Delivery of cytokines by liposomes: I, preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother Emphasis Tumor Immunol 1994; 16: 47-59
96. Qi XR, Maitani Y, Shimoda N, et al. Evaluation of liposomal erythropoietin prepared with reverse-phase evaporation vesicle method by subcutaneous administration in rats. Chem Pharm Bull (Tokyo) 1995; 43 (2): 295-9
97. Maitani Y, Hazama M, Tojo Y, et al. Oral administration of recombinant human erythropoietin in liposomes in rats: influence of lipid composition and size of liposomes on bioavailability. J Pharm Sci 1996 Apr; 85: 440-5
98. Maitani Y, Moriya H, Shimoda N, et al. Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats. Int J Pharm 1999 Aug; 185: 13-22
99. Regulier E, Schneider BL, Deglon N, et al. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts, Gene Ther 1998 Aug; 5 (8): 1014-22
100. Dalle B, Payen E, Regulier R, et al. Improvement of mousethalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Ther 1999 Feb; 6 (2): 157-61
101. Serguera C, Bohl D, Rolland E, et al. Control of erythropoietin secretion by doxycycline or mifeprostone in mice bearing polymer-encapsulated engineered cell. Hum Gene Ther 1999; 10 (3): 375-83
102. Swiss National Science Fondation Adieu la Seringue, voici les implants [online]. Available from URL: www.snf.ch/fr/com/prr/prr_cur_mar19.asp [Accessed 2003 Jan 8]
103. Kessler P, Podsakoff G, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996 Nov; 93: 14082-7
104. Zhou S, Murphy JE, Escobedo JA, et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Ther 1998; 5: 665-70
105. Osborne WRA, Ramesh N, Lau S, et al. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 1995; 92: 8055-8
106. Bohl D, Naffakh N, Heard JM. Long term control of erythropoietin secretion levels by tetracycline in mice transplanted with engineered primary myoblasts. Nat Med 1997; 3: 299-312
107. Rinsch C, Regulier E, Deglon N, et al. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum Gene Ther 1997 Nov 1; 8 (16): 1881-9
108. Bohl D, Salvetti A, Moullier PH, et al. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998; 92: 1512-7
109. Clakson T. Regulated gene expression systems. Gene Ther 2000; 7: 120-5
110. Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999 Jan 1; 283 (5398): 88-91
111. Abruzzese RV, Godin D, Mehta V, et al. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol Ther 2000; 2: 276-87
112. Adam D. Gene therapy may be up to speed for cheats at 2008 Olympics. Nature 2001 Dec 6; 414: 569-70
113. Friedmann T, Koss JO. Gene transfer and athletics: an impending problem. Mol Ther 2001 Jun; 3 (6): 819-20
114. Sommer B, Rinsch C, Payen E, et al. Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol Ther 2002 Aug; 6 (2): 155-61
115. Repoxygem. Fact sheet. Available from URL: www.asda.org.au/resources/Repoxygen1.pdf [Accessed 2003 Jan 17]
116. Jolliffe LK, Middleton SA, Barbone FB, et al. Erythropoietin receptor: application in drug development. Nephrol Dial Transplant 1995; 10 Suppl. 2: 80-4
117. Boulay JL, Paul WE. Haematopoietin sub-family classification based on size, gene organization and sequence homology. Curr Biol 1993; 3: 573-81
118. Bazan JF. Structural design and molecular evaluation of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 1990; 87: 6934-8
119. Darnell JE, Kerr IA, Starck GR. Jak-STAT pathways and transcriptional activation in response to IFNa and other extracellular signalling proteins. Science 1994; 264: 383-6
120. Wells JA, Hormone mimicry. Science 1996; 273: 449-50
121. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273: 458-63
122. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the Epo receptor complex at 2.8 A. Science 1996; 273: 464-71
123. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 1999; 10 (1): 18-23
124. Caravella JA, Lyne PD, Richards WG. A partial model of the erythropoietin receptor complex. Proteins 1996; 24: 394-401
125. Barbone FP, Middleton SA, Johnson DL, et al. Mutagenesis studies of the human erythropoietin receptor. J Biol Chem 1997; 272 (8): 4985-92
126. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotech 1997; 15: 1261-5
127. Livnah O, Johnson DL, Stura EA, et al. An antagonist peptide-Epo receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 1998; 5: 993-1003
128. Ballinger MD, Wells JA. Will any dimmer do? Nat Struct Biol 1998; 5 (11): 938-40
129. Johnson DL, Farrell FX, Barbone FP, et al. Amino terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997; 4: 939-50
130. McConnell SJ, Dinh T, Le MH, et al. Isolation of erythropoietin receptor agonist peptides using evolved phage libraries. Biol Chem 1998; 379: 1279-86
131. Naranda T, Wong K, Kaufman RI, et al. Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site. Proc Natl Acad Sci U S A 1999; 96: 7569-74
132. Elliot S, Lorenzini T, Yanaghira D, et al. Activation of the erythropoietin (EPO) receptor by bivalent t anti-Epo receptor antibodies. J Biol Chem 1996; 271: 24691-7
133. Schneider H, Chaovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 1997 Jan; 89 (2): 473-82
134. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 1994; 348: 647-9
135. Watowich Y, Yoshimura A, Longmore GD, et al. Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci U S A 1992; 89: 2140-5
136. Watowich Y, Hilton DS, Lodish HF. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol 1994; 14: 3535-49
137. Li JP, D'Andrea AD, Lodish HF, et al. Activation of cell growth by binding of Friend Spleen focus forming gp55 glycoprotein to the erythropoietin receptor. Nature 1990; 343: 762-4
138. Qureshi SA, Kim RM, Konteatis Z, et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci U S A 1999; 96 (21): 12156-61
139. Navia MA, Chatturvedi PR. Design principles for orally bioavailable drugs. Drug Disc Today 1996; 1: 179-89
140. Barbone FP, Johnson DL, Farrell FX, et al. New epoietin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999; 14 (2): 80-4
141. Abraham DJ, Wireko FC, Randad RS, et al. Allosteric modifiers of hemoglobin: 2-[4-[(3,5-Disubstituted anilino)carbonyl]-methylphenoxy]-2-methylpropionic acid derivatives that lower whole blood, and in vivo in rats. Biochemistry 1992; 31: 9141-9
142. Perutz MF, Poyart C. Bezafibrate lowers oxygen affinity of haemoglobin. Lancet 1983; II: 881-2
143. Lalezeri I, Rahbar S, Lalezeri P, et al. LR16, a compound with potent effects on the oxygen affinity of haemoglobin on blood cholesterol and on low density lipoprotein. Proc Natl Acad Sci U S A 1988 Aug; 85: 6117-21
144. Lalezari I, Lalezari P, Poyart C, et al. New effectors of human hemoglobin: structure and function. Biochemistry 1990 Feb; 29: 1515-23
145. Randad RS, Mahran MA, Mehanna AS, et al. Allosteric modifiers of haemoglobin design, synthesis, testing and structure-allosteric activity relationship of novel haemoglobin oxygen affinity decreasing agents. J Med Chem 1991; 34: 752-7
146. Uchida K, Reilly MP, Abraham DJ, et al. Effect of an allosteric modifier of haemoglobin, RSR-4, on oxygen affinity and oxygen saturation of haemoglobin in rabbits. Jpn J Physiol 1998; 48: 439-44
147. Wahr JA, Gerber M, Venitz J, et al. Allosteric modification of oxygen delivery by haemoglobin. Anesth Analg 2001; 92: 615-20
148. Kleinberg L, Grossman SA, Piantadosi S, et al. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol 1999; 17 (8): 2593-603
149. Eichelbronner O, Sielenkamper A, D'Almeida M, et al. Effects of FI (O (2)) on hemodynamic responses and O (2) transport during RSR13-induced reduction in P (50). Am J Physiol 1999 Jul; 277 (1 Pt 2): 290H-8H
150. Phelps Grella M, Danso-Danquah R, Safo MK, et al. Synthesis and structure-activity relationships of chiral allosteric modifiers of hemoglobin. J Med Chem 2000; 43: 4726-37
151. Youssef AM, Safo KM, Danso-Danquah R, et al. Synthesis and X-ray studies of chiral allosteric modifiers of hemoglobin. J Med Chem 2002; 45: 1184-95
152. Breidbach A, Catlin DH. RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2001; 15 (24): 2378-82
153. 2 delivery in dog muscle in situ. J Appl Physiol 1998; 84 (3): 995-1002
154. Amberson WR, Flexner J, Steggerda FR, et al. On the use of Ringer-Locke solutions containing haemoglobin as a substitute for normal blood in mammals. J Cell Comp Physiol 1934; 5: 359-82
155. Amberson WR, Jennings JJ, Rhode CM. Clinical experience with haemoglobin-saline solutions. J Appl Physiol 1949; 1: 469-89
156. Bunn HF. Subunit dissociation of certain abnormal human haemoglobins. J Clin Invest 1969; 48: 126-38
157. Mok W, Chen DE, Mazur A. Cross-linked haemoglobins as potential plasma protein extenders. Fed Proc 1975; 34: 1458-60
158. Przybelski RJ, Daily EK, Kisicki JC, et al. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked haemoglobin solution. Crit Care Med 1996; 24 (12): 1993-2000
159. Sloan EP, Koenisberg M, Gens D, et al. Diaspirin cross-linked haemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock. JAMA 1999; 282: 1857-64
160. Winslow RM. Blood substitutes. Curr Opin Hematol 2002; 9: 146-51
161. Lee R, Atsumi N, Jacobs EE, et al. Ultrapure, stroma-free, polymerised bovine haemoglobin solution: evaluation of renal toxicity. J Surg Res 1989; 47: 407-11
162. Hill SE. Oxygen therapeutics: current concepts. Can J Anaesth 2001; 48 (4 Suppl.): 32-40
163. Sanders KE, Ackers G, Sligar S. Engineering and design of blood substitutes. Curr Opin Struct Biol 1996; 6: 534-40
164. Jia L, Bonaventura C, Bonaventura J, et al. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996; 380: 221-6
165. Privalle C, Talarico T, Keng T, et al. Pyridoxalated haemoglobin polyoxyethylene: a nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock. Free Radic Biol Med 2000; 28 (10): 1507-17
166. D'Agnillo F, Chang TMS. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nat Biotech 1998; 16: 667-71
167. Kluger R, Wodzinska J, Jones RT, et al. Three-point cross-linking potential red cell substitutes from the reaction of trimesoyl tris (methylphosphate) with hemoglobin. Biochemistry 1992 Aug; 31: 7551-9
168. Bucci E, Razynska A, Kwansa H, et al. Production and characteristics of an infusible oxygen-carrying fluid based on hemoglobin intramolecularly cross-linked with sebaci acid. J Lab Clin Med 1996 Aug; 128 (2): 146-53
169. Buehler PW, Mehendale S, Wang H, et al. Resuscitative effects of polynitroxylated α-cross-linked haemoglobin following severe hemorrhage in the rat. Free Radic Biol Med 2000; 29 (8): 764-74
170. Nakai K, Togashi H, Yasukohchi T, et al. Preparation and characterization of SNO-PEG-haemoglobin as a candidate for oxygen transporting material. Int J Artif Organs 2001; 24: 322-8
171. Marden MC, Kiger L, Poyart C, et al. Modulation of the oxygen affinity of cobalt-porphyrin by globin. FEBS Lett 2000; 472: 221-4
172. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotech 1998 Jul; 16 (7): 672-6
173. Kumar R, Manjula BN. Red cell substitutes: basic principles and clinical application. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. New York: Marcel Dekker, 1997: 309-24
174. Dieryck W, Pagnier J, Poyart C, et al. Human haemoglobin from transgenic tobacco. Nature 1997 Mar; 386 (6620): 29-30
175. Komiyama N, Tame J, Nagai K. A hemoglobin-based blood substitute: transplanting a novel allosteric effect of crocodile Hb. Biol Chem 1996 Sep; 377: 543-8
176. Chang TMS. Future prospects for artificial blood. Trends Tech 1999; 17: 61-7
177. Djordevich L, Ivankovich AD. Progress in development of synthetic erythrocytes made by encapsulation of haemoglobin. Adv Exp Med Biol 1988; 238: 171-97
178. Rabinovici R, Rudolph AS, Feuerstein G. Characterization of hemodynamic, hematologic, and biochemical responses to administration of liposome-encapsulated haemoglobin in the conscious, free moving rat. Circ Shock 1989; 29: 115-32
179. 2 affinity. Am J Physiol 1999 Feb; 276 (2 Pt 2): 553-62H
180. Usuba A, Motoki R, Miyauchi Y, et al. Effect of neo red cells on the canine hemorrhagic shock model. Int J Artif Organs 1994; 14: 739-44
181. Rabinovici R, Rudolph AS, Vernick J, et al. A new salutary resuscitative fluid: liposome encapsulated haemoglobin/hypertonic saline solution. J Trauma 1993; 35: 121-6
182. Farmer MC, Johnson SA, Beissinger RL, et al. Liposome-encapsulated haemoglobin: a synthetic red cell. Adv Exp Med Biol 1988; 238: 161-70
183. Tsuchida E. Synthesis and characterization of artificial red cell (ARC). Biomater Artif Cells Immobilization Biotechnol 1992; 20 (2-4): 337-44
184. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracles solutions? Anesth Analg 1996; 82: 390-405
185. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated haemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes, role of complement and inhibition by soluble CRI and anti-C5a antibody. Circulation 1999; 99: 2302-9
186. Chang TMS, Yu WP. Nanoencapsulation of haemoglobin and red blood cell enzymes based on nanotechnology and biodegradable polymer. In: Chang TMS, editor. Blood substitutes: principles, methods, products and clinical trials. Basel: Karger AG, 2000: 216-31
187. Haney CR, Buehler PW, Gutil A. Purification and chemical modifications of haemoglobin in developing based oxygen carriers. Adv Drug Deliv Rev 2000 Feb 28; 40 (3): 153-69
188. Carmichael FJ. Recent developments in haemoglobin-based oxygen carriers: an update on clinicals trials. Transfus Apheresis Sci 2001 Feb; 24 (1): 17-21
189. Hughes Jr GS, Yancey EY, Albrecht R, et al. Haemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Clin Pharmacol Ther 1995; 58 (4): 434-43
190. Riess JG. Fluorocarbon-based in vivo oxygen transport and delivery systems. Vox Sang 1991; 61: 225-39
191. 2 dissociates curves of blood Fluosol-DA 20% mixtures. Adv Exp Med Biol 1985; 191: 453-61
192. Habler O, Kleen M, Messmer K. Clinical potential of intravenously administered perfluorocarbons. Acta Anaesthesiol Scand Suppl 1997; 111: 256-8
193. Sakas DE, Whittaker KW, Crowell RM, et al. Perfluorocarbons: recent developments and implications for neurosurgery. J Neurosurg 1996; 85: 248-54
194. Kaufman RJ. Clinical development of perfluorocarbon-based emulsions are red cell substitutes. In: Winslow RM, Vandergriff KD, Intaglietta M, editors. Blood substitutes: physiological basis of efficacy. Boston (MA): Birkhauser, 1995: 53-75
195. Goodnough LT, Scott MG, Monk TG. Oxygen carriers as blood substitutes. Clin Orthop 1998; 357: 89-100
196. Faithfull NS. Mechanisms and efficacy of fluorochemical oxygen transport and delivery. Artif Cells Blood Substit Immobil Biotechnol 1994; 22 (2): 181-97
197. Mitten RM, Burgan AR, Hamblin A, et al. Dose related biodistribution and elimination of 100% PFOB emulsion. Biomater Artif Cells Artif Organs 1988; 16 (1-3): 683-4
198. Audran M, Krafft MP, De Ceaurriz J, et al. Assay method for the perfluorooctyl bromide (perflubron) in rat blood by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1999 Aug; 734 (2): 267-76
199. Audran M, Krafft MP, De Ceaurriz J, et al. Determination of perfluorodecalin and perfluoro-N-methylcyclohexylpiperidine in rat blood by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000: 745: 333-43
200. Rivier L. The doping products of tomorrow. Ann Toxicol Analytique 2000; 12 (1): 79-89
201. Mathurin JC, De Ceaurriz J, Audran M, et al. Detection of perfluorocarbons in blood by headspace solid-phase microextraction combined with gas chromatography/mass spectrometry. Biomed Chromatogr 2001; 15 (7): 443-51
202. Schumacher YO, Schmid A, Dinkelmann S, et al. Artificial oxygen carriers: the new doping threat in endurance sport? Int J Sports Med 2001; 22: 566-71